Dear EditorPrior to the explosion of gene targeting technology, considerable biochemical and cell-based experiments suggested a role for DNA polymerase β (pol β) in DNA repair. Since its initial discovery in 1971 [1], the enzyme that was to eventually be designated pol β [2,3] was unique in its enzymatic properties [4][5][6] as compared to the other newly characterized mammalian DNA polymerases alpha (pol α), gamma (pol γ) and delta (polδ) [1,7]. Of the four eukaryotic DNA polymerases identified by 1977, pol β soon earned the moniker of 'the' DNA repair polymerase [8][9][10][11]. These early studies defined a role for pol β in repair using isolated nuclei or nuclear extracts, monitoring the incorporation of radioactive nucleosides following ultraviolet (UV) light-induced DNA damage [8][9][10][11]. A more definitive role for pol β in excision repair in vitro was demonstrated in 1983, in which complete removal of pyrimidine dimers in DNA was conducted by purified enzyme preparations of pol β, T4 denV (UV endonuclease) and HeLa AP endonuclease II [12]. Although it was subsequently shown that pol α can also carry-out gap-filling DNA synthesis in a base excision repair (BER) reaction [13], the evidence continued to mount in support of pol β acting as 'the' DNA repair polymerase in the nucleus, while pol γ participated in replication and repair in mitochondria [1]. Studies continued to identify a role for pol β in the repair of damage induced by many different DNA damaging agents, including bleomycin [14,15] [21][22][23][24]. Several groups reported complete BER in vitro with pol β and additional purified proteins [22,23,25]. Although it was demonstrated in heterologous systems (E. coli and Saccharomyces cerevisiae) that pol β can conduct DNA replication and repair in vivo [26,27], it was not until a mouse gene knockout was made that the specificity of the repair conducted by pol β was defined [28].Characterization of the pol β knockout mouse [29,30] [34,54,55]; among other studies too numerous to mention herein. The most definitive and reproducible endpoint that has been used to evaluate pol β *To whom correspondence should be addressed: Robert W. Sobol, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Research Pavilion, Suite 2.6, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, Phone: 412-623-7764, Fax: 412-623-7761, e-mail: rws9@pitt.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript participation in repair in vivo is survival following DNA damage such as exposure to alkylating agen...